CN102078351B - Composition for treating cancer - Google Patents
Composition for treating cancer Download PDFInfo
- Publication number
- CN102078351B CN102078351B CN201110020277A CN201110020277A CN102078351B CN 102078351 B CN102078351 B CN 102078351B CN 201110020277 A CN201110020277 A CN 201110020277A CN 201110020277 A CN201110020277 A CN 201110020277A CN 102078351 B CN102078351 B CN 102078351B
- Authority
- CN
- China
- Prior art keywords
- cancer
- group
- experiment
- radix
- liver
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention relates to application of a Chinese medicine composition containing two active components of acanthopanax root extracts and paecilanyces hepialid mycelium in treating of the cancers, wherein the cancers comprise solid tumor, preferably liver cancer, lung cancer, breast cancer, esophageal cancer, gastric cancer, nasopharyngeal carcinoma, ovarian cancer, bladder cancer, rectal cancer, skin cancer and lymphoma, further preferably the liver cancer, in particular the liver cancer with cirrhosis of liver and ascites. The preparation containing the acanthopanax root extracts and the paecilanyces hepialid mycelium does not have an amazing therapeutic effect on human affection-tumors, but also effectively utilizes the resources and protects the ecological environment.
Description
Technical field
The present invention relates to use a kind of compositions of treating cancer, the Paecilomyces hepiali Chen et Dai Mycelia of Radix Et Caulis Acanthopanacis Senticosi extract associating is specifically treated cancer, and wherein said composition can be processed dosage forms such as capsule, electuary, tablet, drop and oral liquid as required.
Background technology
Cordyceps Cordyceps sinensis (Berk) Sacc is Stroma and the larva cadaveric complex of Clavicipitaceae fungi autoeciousness on Vespertilio moth insecticide Cordyceps Vespertilio moth larvae; It is the rare Chinese medicine of China's tradition strengthening by means of tonics, in Chinese herbal medicine and health product, uses in a large number.Along with the increasingly extensive and unordered madness that natural cs is used on market is excavated, the resource of natural cs is exhausted just rapidly.China has begun the research work of artificial culture Paecilomyces hepiali Chen et Dai Mycelia in early 1980s, and has obtained remarkable progress.The fungus composition that extraction separation obtains in the artificial fermentation Cordyceps mycelium main source natural cordyceps.So far, microorganism scholar report kind surplus the fungus bacterium pearl of extraction separation and evaluation reaches ten from natural cs, wherein the evaluation again of some strains postmenstruation is same strain in fact.State approval application peacilomyce hepiahi bacterium (Paecilanyces hepialj) and Hirsutlla sinensis bacterium (Hirsutella sinensis) tunning use in Chinese herbal medicine and health product as the Cordyceps mycelium of artificial fermentation at present.Wherein peacilomyce hepiahi bacterium (Paecilanyces hepiali) is by the extensive use in treatment cancer and health product of a plurality of countries such as the U.S., Japan, Korea S.
Because isolated different bacterium pearls on different types of Cordyceps even the same Cordyceps, or the different places of production of same Cordyceps, effective ingredient is often different, and its drug effect or function are also inequality.
In CN101653466A, disclosed the compositions of the treatment cancer that contains toad clothing, Radix Et Caulis Acanthopanacis Senticosi and Cordyceps mycelium, Cordyceps mycelium wherein is natural prodcuts.Receive raw-material restriction; Peacilomyce hepiahi bacterium (Paecilanyces hepjali) that the inventor attempts to use with present state approval and Hirsutlla sinensis bacterium (Hirsutella sinensis) tunning are as the substitute products of Cordyceps mycelium; Its therapeutic effect is wondrous; Wherein the effect of Radix Et Caulis Acanthopanacis Senticosi extract associating Paecilomyces hepiali Chen et Dai Mycelia also is superior to Radix Et Caulis Acanthopanacis Senticosi extract and Cordyceps mycelium effect of Combination, on the basis of this discovery, has accomplished the present invention.
Summary of the invention
One of main purpose of the present invention provides a kind of compositions evident in efficacy; Be used to treat cancer; The said preparation compositions comprises Radix Et Caulis Acanthopanacis Senticosi extract and two kinds of active component of Paecilomyces hepiali Chen et Dai Mycelia; The ratio of the weight of two kinds of active component in compositions is a Radix Et Caulis Acanthopanacis Senticosi extract: Paecilomyces hepiali Chen et Dai Mycelia is: 1-3: 3-9, preferred 1: 3.
Two of main purpose of the present invention is above-mentioned compositions that contain Radix Et Caulis Acanthopanacis Senticosi extract and Paecilomyces hepiali Chen et Dai Mycelia of preparation taking convenience, and said preparation is prepared into common formulations: the form like capsule, tablet, electuary, drop or oral liquid can make things convenient for patient to take.Certainly these preparations can be used as drug administration and also can be used as health food and take.
The specific embodiment
The present composition with containing Radix Et Caulis Acanthopanacis Senticosi extract and Paecilomyces hepiali Chen et Dai Mycelia is treated cancer; Wherein said cancer is a solid tumor; Multiple cancers such as preferred hepatocarcinoma, pulmonary carcinoma, breast carcinoma, esophageal carcinoma, gastric cancer, nasopharyngeal carcinoma, ovarian cancer, bladder cancer, rectal cancer, cervical cancer, skin carcinoma, the brain cancer, osteocarcinoma and lymphatic cancer; Further preferred hepatocarcinoma, pulmonary carcinoma, breast carcinoma, esophageal carcinoma, gastric cancer, ovarian cancer, rectal cancer, cervical cancer, lymphatic cancer; Further preferred hepatocarcinoma, pulmonary carcinoma, esophageal carcinoma, lymphatic cancer, the liver cancer efficacy that liver cirrhosis and ascites have particularly occurred is especially obvious.
The compositions that contains Radix Et Caulis Acanthopanacis Senticosi extract and Paecilomyces hepiali Chen et Dai Mycelia of the present invention can the cost of manufacture those skilled in the art being seen various dosage forms usually, like capsule, electuary, tablet, drop and oral liquid etc.
Radix Et Caulis Acanthopanacis Senticosi is the dry root and rhizome of Araliaceae Radix Et Caulis Acanthopanacis Senticosi.Radix Et Caulis Acanthopanacis Senticosi and Radix Ginseng belong to Araliaceae together, are sibling species not, have the effect of activating blood circulation to dissipate blood stasis, dredge the meridian passage, can blood vessel dilating, improve the blood flow of parenchymal visceras such as the heart, brain, kidney, increase tissue to anoxybiotic toleration etc.Be used for Radix Et Caulis Acanthopanacis Senticosi extract of the present invention and be water extract or alcohol extract that conventional method is extracted, specifically can referring to (Liang Li's heavily fortified point etc., " experimentation of Radix Et Caulis Acanthopanacis Senticosi extract antitumor action ", the time precious traditional Chinese medical science traditional Chinese medicines, 2006 the 17th the 7th phases of volume).But this only is to provide as an example, the present invention is not constituted any restriction.
" Radix Et Caulis Acanthopanacis Senticosi extract " and " Paecilomyces hepiali Chen et Dai Mycelia " preparation of compositions method: take by weighing an amount of " Radix Et Caulis Acanthopanacis Senticosi extract " and " Paecilomyces hepiali Chen et Dai Mycelia " and cross 80 mesh sieves respectively, mixing and stirring is subsequent use then.
Paecilomyces hepiali Chen et Dai Mycelia is to adopt from Qinghai cajaput area to produce separating obtained Clavicipitaceae fungus peacilomyce hepiahi strain Cs-4 bacterial strain the fresh peacilomyce hepiahi bacterium, through the mycelial dried powder of liquid submerged fermentation gained.
Embodiment
Embodiment 1: capsule finished product
Take by weighing Paecilomyces hepiali Chen et Dai Mycelia 149 grams, cross 80 mesh sieves; Take by weighing Radix Et Caulis Acanthopanacis Senticosi extractum powder 50 grams, cross 80 mesh sieves, mix adding 1 gram magnesium stearate, mix homogeneously divides 100 Capsuleses of packing into, and every contains crude drug 0.2 gram; With above-mentioned capsulation, sealing, irradiation sterilization is capsule finished product.Embodiment 2, the present invention contain the anti-tumor experiment of the Chinese medicine composition of Radix Et Caulis Acanthopanacis Senticosi extract, Paecilomyces hepiali Chen et Dai Mycelia
1. test objective:
Observe: " Radix Et Caulis Acanthopanacis Senticosi extract, Cordyceps mycelium " prescription is hereinafter to be referred as " experiment A group ", and " Radix Et Caulis Acanthopanacis Senticosi extract, Paecilomyces hepiali Chen et Dai Mycelia " of the present invention prescription is hereinafter to be referred as " experiment B group "; " Radix Et Caulis Acanthopanacis Senticosi extract, Hirsutlla sinensis mycelium " prescription is hereinafter to be referred as " experiment C group "; " Radix Et Caulis Acanthopanacis Senticosi extract " compares the curative effect of Mice Bearing Lewis Lung Cancer, S180 sarcoma and H22 hepatocarcinoma hereinafter to be referred as " experiment D group ".
2. receive the reagent thing:
Title: " experiment A group ", " experiment B group " ", " experiment C group " ", " experiment D group ".The unit of providing: Chanbao Organism Science and Technology Co., Ltd., Shanghai
Sample preparation: get the respective amount sample, add a small amount of Tween 80 hydrotropy, add 0.5%CMC-Na solution to aequum (each dosage 0.5ml/ Mus) more gradually.
3. laboratory animal:
3.1 source kind strain: Kunming mouse, the quality certification number are: " Shanghai is moving closes the card word No. 201 ".C
57The BL/6 mice is provided by Shanghai Chinese Academy of Sciences animal center, and the quality certification number is: " Shanghai is moving closes the card word No. 85 "
3.2 body weight: 19.5 ± 1.5 grams
3.3 sex: take Kunming mouse, male and female half and half, every batch of test is used with a kind of sex.
3.4 number of animals: every group of 10 Kunming mouses.Each test group and positive controls are 10 for every group, and negative control group is 20.
4. tumor source: Mice Bearing Lewis Lung Cancer, S180 sarcoma, H22 liver cancer model, go down to posterity by Chanbao Organism Science and Technology Co., Ltd., Shanghai and to keep.
5. dosage setting:
Clinical trial: respectively establish a dose groups, be 4g/kg dosage, the therapeutic scheme of ig * 10qd.Positive controls cyclophosphamide (CTX) 15mg/kg, negative control group is given corresponding solvent.
6. dosage regimen: test group and matched group are gastric infusion, once a day, and continuous ten days.
7. experimental control:
Negative control is given coordinative solvent.
Positive control is cyclophosphamide (CTX), and the injectable powder that Hua Lian, Shanghai pharmacy group company produces is prepared with normal saline.
8. test key step:
8.1 the subcutaneous vaccination of Mice Bearing Lewis Lung Cancer toes is tested: get eugonic solid tumor mice, aseptic condition takes out tumor down, is prepared into 1-2 * 10 with the homogenate method
7/ ml cell suspension, with the right toes subcutaneous vaccination of the every Mus of corresponding host 0.05ml/ only, about ten day put to death each treated animal by the administration of EXPERIMENTAL DESIGN scheme next day, cuts open to get lotus tumor toes and weigh, and calculates tumor control rate by following formula:
Tumor control rate=(the average tumor of the average tumor weight/matched group of the average tumor weight-administration of matched group group is heavy] * 100
8.2 the clinical trial to S180 sarcoma and H22 hepatocarcinoma axil subcutaneous vaccination solid tumor: get eugonic solid tumor mice, aseptic condition takes out tumor down, is prepared into 1-2 * 10 with the homogenate method
7/ ml cell suspension, with the right axil subcutaneous vaccination of the every Mus of corresponding host 0.2ml/ only, about ten day put to death each treated animal by the administration of EXPERIMENTAL DESIGN scheme next day, cuts open to get tumor and weigh, and calculates tumor control rate by following formula:
Tumor control rate=(the average tumor of the average tumor weight/matched group of the average tumor weight-administration of matched group group is heavy] * 100
Table 1. sample is to one of inhibition test of Mice Bearing Lewis Lung Cancer (toes subcutaneous vaccination)
Compare * * * P＜0.01 with negative control group
Table 2. sample is to one of inhibition test of mice S180 sarcoma
Compare * * * P＜0.01 with negative control group
Table 3. sample is to one of inhibition test of mice H22 hepatocarcinoma
Compare P＜0.01 with negative control group
9. result of the test:
Experiment A group, experiment B group, experiment C group, experiment D group are irritated stomach single-dose one day to kunming mice and with the therapeutic scheme of 4g/kg dosage ig * qd twice examination experimental result tumour inhibiting rate of Mice Bearing Lewis Lung Cancer toes subcutaneous vaccination are seen for details table 1;
Experiment A group, experiment B group, experiment C group, experiment D group see table 2 for details to S180 sarcoma experimental result tumour inhibiting rate
Experiment A group, experiment B group, experiment C group, experiment D group to the anti-tumor experiment of H22 hepatocarcinoma as a result tumour inhibiting rate see table 3 for details
10. test brief summary:
10.1. it is similar with negative control group that experiment A group, experiment B group, experiment C group, experiment D group the weight of animals when clinical trial change, and has certain safety so sample is respectively organized in prompting.
10.2. " experiment A group " antitumor test reaches about 60% Mice Bearing Lewis Lung Cancer, S180 sarcoma and H22 liver-cancer solid tumor antitumous effect;
" experiment B group " experiment antitumor test reaches about 70% Mice Bearing Lewis Lung Cancer, S180 sarcoma and H22 liver-cancer solid tumor antitumous effect;
" experiment C group " experiment antitumor test reaches about 50% Mice Bearing Lewis Lung Cancer, S180 sarcoma and H22 liver-cancer solid tumor antitumous effect;
" experiment D group " antitumor test reaches about 35% Mice Bearing Lewis Lung Cancer, S180 sarcoma and H22 liver-cancer solid tumor antitumous effect;
Experimental result shows that " experiment B group " sample truly has stronger antitumor action, has the prospect of replacement " experiment A group " and " experiment D group ".And experiment all has repeatability.
Significant curative effect has bigger DEVELOPMENT PROSPECT to the compositions of of the present invention containing " Radix Et Caulis Acanthopanacis Senticosi extract " and " Paecilomyces hepiali Chen et Dai Mycelia " having shown unique aspect the treatment cancer.
Claims (5)
1. compositions of treating cancer, wherein the active component in the said composition is Radix Et Caulis Acanthopanacis Senticosi extract and Paecilomyces hepiali Chen et Dai Mycelia, the ratio of the weight of the two is: 1-3: 3-9.
2. compositions as claimed in claim 1, wherein Radix Et Caulis Acanthopanacis Senticosi extract with the ratio of the weight of Paecilomyces hepiali Chen et Dai Mycelia is: 1: 3.
3. compositions as claimed in claim 1 wherein adds 0.5% magnesium stearate.
4. the purposes of the described compositions of claim 1 in the medicine of preparation treatment cancer.
5. the described compositions of claim 1 is in the purposes of preparation in the health food.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201110020277A CN102078351B (en) | 2011-01-07 | 2011-01-07 | Composition for treating cancer |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201110020277A CN102078351B (en) | 2011-01-07 | 2011-01-07 | Composition for treating cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102078351A CN102078351A (en) | 2011-06-01 |
| CN102078351B true CN102078351B (en) | 2012-08-29 |
Family
ID=44084676
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201110020277A Expired - Fee Related CN102078351B (en) | 2011-01-07 | 2011-01-07 | Composition for treating cancer |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102078351B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109077317A (en) * | 2018-07-19 | 2018-12-25 | 深圳市博奥生物科技有限公司 | A kind of lycopene capsules and preparation method thereof |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1109551C (en) * | 2000-07-31 | 2003-05-28 | 赵富清 | Anticancer capsule 'Wushensu' and its extracting and preparing process |
| CN101653466A (en) * | 2009-08-27 | 2010-02-24 | 上海蟾宝生物科技有限公司 | Composition for treating cancers |
-
2011
- 2011-01-07 CN CN201110020277A patent/CN102078351B/en not_active Expired - Fee Related
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1109551C (en) * | 2000-07-31 | 2003-05-28 | 赵富清 | Anticancer capsule 'Wushensu' and its extracting and preparing process |
| CN101653466A (en) * | 2009-08-27 | 2010-02-24 | 上海蟾宝生物科技有限公司 | Composition for treating cancers |
Non-Patent Citations (2)
| Title |
|---|
| 李安陵.关于保健酒的研发思考.《酿酒》.2009,第36卷(第5期),第87-90页. * |
| 王娜等.蝙蝠蛾拟青霉Cs-4对阿霉素肾病大鼠的保护作用.《中国中西医结合杂志》.2010,第30卷(第9期),第957-960页. * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102078351A (en) | 2011-06-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102048959B (en) | Dendrobium candidum compound preparation capable of regulating function of human body in two-way manner and preparation method thereof | |
| CN102600212B (en) | Medicinal health product for immunity enhancement and adjuvant treatment of tumor | |
| CN101380346B (en) | Traditional Chinese composition for treating tumor and production method thereof | |
| CN102861193B (en) | Traditional Chinese medicine composition for treating gastric cancer | |
| CN104013636A (en) | Anti-tumor pharmaceutical use of pentacyclic triterpene saponin compounds of szechuan melandium root | |
| CN102406669B (en) | Chinese medicine composite and preparation method and medicinal preparation thereof | |
| CN102579803A (en) | Medicine for treating post-chemotherapy leucopenia and preparation method thereof | |
| CN1775267A (en) | Kaikoujian extract, Its preparing method and use | |
| CN102078351B (en) | Composition for treating cancer | |
| CN106620284A (en) | Completely-wall-broken ganoderma spore powder rich in spore oil | |
| TWI646964B (en) | Pharmaceutical composition, preparation method and use thereof for reducing side effects of cancer treatment drugs | |
| CN102078352B (en) | Composition for treating cancers | |
| CN107893035A (en) | A kind of culture medium of Hericium erinaceus, sealwort bioconversion mycelium, the mycelial extract of sealwort bioconversion and application thereof | |
| WO2013155885A1 (en) | Application of lucide ganoderma and ginseng medicinal mycoplasm in preparing drugs for treating lung cancer | |
| CN103550718A (en) | Traditional Chinese medicine composition for treating lung cancer | |
| CN102423384B (en) | Traditional Chinese drug preparation for treating lung cancer, and preparation method thereof | |
| CN105267793B (en) | A kind of new application of Chinese medicine composition | |
| CN104257955A (en) | Anti-hepatoma traditional Chinese medicine mixture containing arisaema amurense and production method of anti-hepatoma traditional Chinese medicine mixture | |
| CN104857276B (en) | A kind of Chinese medicine for treating syndrome of deficiency of both qi and yin after malignant tumour Radiotherapy chemotherapy | |
| CN1289104C (en) | Anticancer medicine and its preparation | |
| CN103191268B (en) | Traditional Chinese medicinal composition for treating lung cancer | |
| CN102100836B (en) | Medicinal composition for treating tumors, preparation method thereof and application thereof | |
| CN102940683B (en) | Chinese medicinal compound composition for treating liver cancer and preparation method thereof | |
| CN106421154A (en) | Traditional Chinese medicine composition and traditional Chinese medicine preparation containing Chinese eaglewood wood and having cell repairing, anti-aging and anti-canter functions as well as preparation method of traditional Chinese medicine composition | |
| CN101342203B (en) | Anti-cancer medicine compound lychee formulation and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C53 | Correction of patent for invention or patent application | ||
| CB03 | Change of inventor or designer information |
Inventor after: Yang Mingze Inventor after: Yang Junjie Inventor before: Yang Mingze |
|
| COR | Change of bibliographic data |
Free format text: CORRECT: INVENTOR; FROM: YANG MINGZE TO: YANG MINGZE YANG JUNJIE |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20120829 Termination date: 20150107 |
|
| EXPY | Termination of patent right or utility model |